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Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by early joint contractures, muscular dystrophy, and cardiac
involvement with conduction defects and arrhythmias. So far, only 35% of EDMD cases are genetically elucidated and associated with
EMD or LMNA gene mutations, suggesting the existence of additional major genes. By whole-genome scan, we identiﬁed linkage to the
Xq26.3 locus containing the FHL1 gene in three informative families belonging to our EMD- and LMNA-negative cohort. Analysis of the
FHL1 gene identiﬁed seven mutations, in the distal exons of FHL1 in these families, three additional families, and one isolated case,
which differently affect the three FHL1 protein isoforms: two missense mutations affecting highly conserved cysteines, one abolishing
the termination codon, and four out-of-frame insertions or deletions. The predominant phenotype was characterized bymyopathy with
scapulo-peroneal and/or axial distribution, as well as joint contractures, and associated with a peculiar cardiac disease characterized by
conduction defects, arrhythmias, and hypertrophic cardiomyopathy in all index cases of the seven families. Heterozygous female
carriers were either asymptomatic or had cardiac disease and/or mild myopathy. Interestingly, four of the FHL1-mutated male relatives
had isolated cardiac disease, and an overt hypertrophic cardiomyopathy was present in two. Expression and functional studies demon-
strated that the FHL1 proteins were severely reduced in all tested patients and that this was associated with a severe delay in myotube
formation in the two patients for whom myoblasts were available. In conclusion, FHL1 should be considered as a gene associated with
the X-linked EDMD phenotype, as well as with hypertrophic cardiomyopathy.Introduction
Emery-Dreifuss muscular dystrophy (EDMD [MIM 310300,
181350, 604929]) is a rare hereditary disease characterized
by the triad of 1) early joint contractures of Achilles
tendons, elbows, and rigid spine, 2) childhood onset of
muscle weakness and wasting, usually with a scapulo-
peroneal distribution, and 3) adult-onset cardiac disease
characterized by conduction defects, arrhythmias, and
cardiomyopathy.1 Cardiac disease usually appears as late
as 40 years of age and is the major life-threatening issue
in EDMD because it is often responsible for sudden cardiac
death.2–4 The disease can be transmitted in a recessive
X-linked manner as a result of mutations in EMD (MIM
300384), encoding the emerin protein,5 or in an autosomal
mode with mutations in LMNA (MIM 150330), encoding
the lamin A and C proteins.6,7 Emerin and lamins A and
C are components of the nuclear envelope and interact
with each other. The precise functions of emerin and
lamins A and C remain elusive even if they are thought
to participate in replication, transcription, regulation of338 The American Journal of Human Genetics 85, 338–353, Septemsignaling pathways, chromatin organization, and nuclear
envelope structure.8,9
About 50% of the EDMD patients do not carry muta-
tions in EMD and LMNA and are orphan of molecular diag-
nosis,10–12 thus strongly suggesting the existence of other
causative genes that remain to be discovered. Recently,
sequence variants in SYNE1 and SYNE2 genes (MIM
608441, 608442), encoding nesprin 1 and 2 proteins that
bind both emerin and lamins A and C and form a network
in muscle linking the nucleoskeleton to the inner and
outer nuclear membranes, were identiﬁed in patients
with the EDMD phenotype without EMD or LMNA muta-
tions.12 These results further suggested the genetic hetero-
geneity of EDMD. The clinical phenotypes associated with
these variants ranged from almost asymptomatic patients
withmoderately increased creatine kinase to patients man-
ifesting muscular dystrophy combined with severe dilated
cardiomyopathy.12
In order to identify other genes responsible for the
EDMDphenotype, we performed a whole-genome analysis
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disease to chromosome X in three families with a common
locus containing the FHL1 gene (MIM 300163).
FHL1 is composed of eight exons (Ensembl no.
ENSG00000022267, NCBI no. NC_000023.9). The ﬁrst
two are thought to be noncoding, and the others are
alternatively spliced and transcribed into three major
protein isoforms. FHL1 proteins belong to a protein family
containing four and a half LIM domains (Lin-11, Isl-1,
Mec3), which are highly conserved sequences constituted
by two zinc ﬁngers in tandem, implicated in numerous
interactions. Each of the two zinc ﬁngers contains four
highly conserved cysteines linking together one zinc ion.13
The main isoform FHL1A is predominantly expressed in
striated muscles.14,15 The two other isoforms, FHL1B and
FHL1C, less abundant, are expressed in striated muscles
and also in brain and testis, respectively.16–18 FHL1A,
FHL1B, and FHL1C are, respectively, composed of 4.5, 3.5,
and 2.5 LIMdomains. Alternative splicing leads to different
domains in the C-terminal part of FHL1B and FHL1C,
which correspond to nuclear import and export signals in
FHL1B and to the RBP-J binding domain in FHL1B and
FHL1C.16–18 FHL1A can be localized to the sarcolemma,
sarcomere, and nucleus of muscle cells.16,18 It has been
implicated in sarcomere assembly by interacting with
myosin binding protein-C.19 FHL1C has been shown to
modulate transcription factor activities, in particular by
inhibiting RBP-J transactivation.14 Recently, three distinct
myopathies have been annotated with mutations in FHL1:
the X-linked myopathy with postural muscle atrophy and
generalized hypertrophy, or X-MPMA20 (MIM 300696),
the X-linked dominant scapuloperoneal myopathy, or
X-SM21 (MIM 300695), and the reducing body myopathy,
or RBM22 (MIM 300717).
We report here seven FHL1mutations responsible for the
EDMD phenotype in a total of six families and one isolated
case, further extending the spectrum of FHL1-related
diseases. In contrast to all previously described mutations,
patients with EDMD were found to carry mutations in
distal exons (5 to 8) differently affecting all three FHL1
isoforms. Moreover, four of these mutations are insertion
or deletionmutations leading to truncated proteins, which
have not been described for FHL1 so far. Functional anal-
yses showed that FHL1 expression was highly decreased
and not detected in sarcomeres in patient muscles. More
importantly, there was a substantial delay in muscle differ-
entiation of cultured primary myoblasts from patient skel-
etal muscles.
Subjects and Methods
This collaborative study was conducted up to April 2008 among
more than 2200 patients referred to our institutions for routine
diagnostic analysis of EMD and LMNA genes because they
presented clinical features suggesting EMD- and/or LMNA-related
skeletal muscle and/or cardiac disease. Referring physicians were
systematically asked toprovidedetailed clinical data (at leastneuro-
logical examination, electrocardiography, echocardiography,The Americanand respiratory evaluations), as well as the existence of positive
family history. Results of creatine kinase (CK) measurement and
muscle histology, as well as previous genetic analyses, were also
systematically obtained when available. All materials (blood and
muscle biopsies) from patients and controls included in this study
were taken with the informed consent of the donors and with
approval of the local ethical boards. All the procedures followed
were in accordance with the ethical standards of the responsible
committeeonhumanexperimentation (institutional andnational).
Clinical Assessment: Deﬁning the EDMD Phenotype
Inclusion Criteria and Selecting Families
for Whole-Genome Scan
We ﬁrst aimed to deﬁne a clinically homogeneous EDMD patient
population. According to classical EDMD diagnostic criteria,1,23,24
the coexistence of the following clinical features was required:
slowly progressive muscle wasting and weakness, either in a
humero-peroneal, proximal, or diffuse distribution; early joint
contractures involving spine (rigid spine and/or stiff neck)
and limb joints (elbows, ankles, etc.); and cardiac disease including
rhythm and conduction disturbances, with or without cardiomy-
opathy. The presence of such cardiac disease was not a prerequisite
up to 40 years of age. An overt dilated or hypertrophic cardiomyop-
athywas notmandatory, because EDMDmajor cardiologic features
are classically based on the coexistence of conduction defects and/
or arrhythmias.1 All geneticmodes of inheritance were considered.
In addition, when clinical data were not conclusive, other genetic
defects leading to neuromuscular diseases resembling EDMD were
also excluded.25 Blood sampling forDNAextractionwas performed
in accordance with standard procedures.
Muscle Biopsy, Histochemistry,
and Immunohistochemistry
Prior to this study, skeletal muscle biopsies were performed for
diagnostic purpose in the index cases of the seven families, and
we retrospectively obtained muscle biopsy records. Of note,
patients F11-5 and F1328-4 had two muscle biopsies.
We also had access to muscle sections from patients F8-6, F11-5,
F997-8 and the two muscle biopsies from patient F1328-4 and
a 30-year-old male control (Table S1, available online). Muscle
specimens were frozen in isopentane cooled in liquid nitrogen,
and 8 mm and 10 mm cryostat sections were used for histochemical
and immunohistochemical techniques. Morphological analysis of
muscle was made with the use of routine histological stainings:
hematoxylin and eosin (HE), gomori trichrome (GT), and mena-
dione-nitroblue tetrazolium (NBT) staining in the absence of the
substrate a-glycerophosphate.
Immunohistochemical studies were performed in patients F8-6,
F997-8, and F1328-4 and in the male control. Primary antibodies
directed against human desmin (Dako-Desmin, D33, 1:1000;
Dako, Carpinteria, CA, USA); human aB-crystallin (NLC-ABCrys,
1:50, Novocastra, Newcastle, UK); human myotilin (NLC-myoti-
lin, 1:50, Novocastra) were used. A mixture of rabbit and mouse
secondary antibodies was incubated according to the standard
Ventana Nexes System procedure and colored with peroxydase
reaction 3030-diaminobenzidine. A set of control slides was pre-
pared without primary antibodies. For patients F83-4, F321-3,
and F1292-1, no frozen muscle was available for immunohisto-
chemical studies.
Immunoﬂuorescence analysis was performed for FHL1, lamin A
and C, and emerin on longitudinal and transversal sections ofJournal of Human Genetics 85, 338–353, September 11, 2009 339
patients F997-8 and F1328-4 and one healthy control. After ﬁxa-
tion with 2% para-formaldehyde, blocked with 4% BSA in PBS,
the muscle sections were stained with rabbit polyclonal anti-
FHL1 (1:100, ARP34378_T100; Aviva Systems Biology, San Diego,
CA, USA) directed against part of the LIM4 domain of FHL1A,
mouse monoclonal anti-lamin A and C, or anti-emerin (1:100,
4A7 and MANEM5, respectively, both kindly provided by Glen
Morris, NEWI, UK). Incubation of the primary antibody was per-
formed overnight at 4C. After 15 min of rinsing in PBS, the
sections were incubated with Alexa-ﬂuor 488 goat anti-rabbit or
goat anti-mouse IgG (1:500, Invitrogen).
Whole-Genome Scan and Linkage Analysis
Genome-wide analysis was performed on six informative families
with the use of 250K SNP NspI chips from Affymetrix (Santa Clara,
CA, USA). So that a minimal genotyping error rate was ensured,
genotype calls were ﬁrst determined on a collection of more
than 300 individuals, with both the BRLMM and Birdseed algo-
rithms implemented in the apt-probeset-genotype procedure
(Affymetrix power tools V 1.8.5). For the Birdseed algorithm, the
250K_NSP deﬁnition ﬁles, available on the Broad Institute web-
site, were used. Genotypes with conﬁdence scores higher than
0.30 for BRLMM or 0.05 for Birdseed or discordance between
the two algorithms were ﬂagged as no call. Markers having
a minimum allele frequency greater than 0.2 and a call rate supe-
rior to 0.98 were selected. These steps retained 63,776 SNPs on
autosomes and 1680 on chromosome X. Genome-wide linkage
analysis was performed with MERLIN v1.1.226 and its speciﬁc
version for chromosome X (MINX), assuming a recessive mode
of inheritance and a complete penetrance for homozygous
subjects or hemizygous males on the X chromosome. Allelic
frequencies were considered equal in the population, and the
position map was estimated by the marker physical position
expressed in megabases. Multipoint LOD scores were then
computed at each marker position with Merlin. For accommoda-
tion of marker-marker linkage disequilibrium27 due to the SNP
map density, analyses were also performed on clusters of consec-
utive markers for which r2 was greater than 0.40 (option–rsq
0.40 of Merlin).
Genomic DNA Ampliﬁcation and Sequencing of FHL1
Coding exons and intronic ﬂanking regions of FHL1 were ampli-
ﬁed by touch-down PCR (Taq polymerase GOLD, Applied Biosys-
tems, Courtaboeuf, France) with the use of 80 ng of genomic
DNA (primer sequences detailed in Table S2). PCR fragments
were puriﬁed with the use of multiscreen plates on the Manifold
system (Millipore, Saint Quentin en Yvelines, France) and
sequenced with the Big Dye Terminator v.1.1 Cycle Sequencing
Kit (Applied Biosystems). Collected sequence data were analyzed
with SeqScape v.2.5 (Applied Biosystems) and Sequencher v.4.7.
The identiﬁed mutations were checked on DNA of 200 healthy
unrelated control subjects.
Cell Culture, Differentiation Study,
and Immunoﬂuorescence
Primary myoblast cultures were obtained from fresh muscle
biopsies from patients F321-3 and F997-5 and from three healthy
age-matched male control subjects (Table S1). Primary myoblasts
were expanded in proliferation medium containing 80% MYO1
medium (Hyclone, Thermo Scientiﬁc, Berbie`res, France), 20%
FBS (GIBCO, Invitrogen, Cergy Pontoise, France), 50 mg/ml genta-340 The American Journal of Human Genetics 85, 338–353, Septemmycin (Invitrogen, Cergy Pontoise, France), 10 ng/ml human
recombinant bFGF (R&D Systems, Lille, France), 106 M dexa-
methasone (Merck, Fontenay sous Bois, France) at 37C, and 5%
CO2. All myoblast cultures from patients and from control
subjects were enriched in myoblasts by magnetic cell sorting
with the use of anti-CD56 to reach at least 95% of myoblasts.
Myoblast differentiation was induced by switching conﬂuent
myoblasts to differentiation medium (DMEM containing 4.5g/L
glucose, pyruvate, antibiotics without FBS) on 0.5% gelatin-coated
dishes. Cells were collected at different times after the addition of
differentiation medium. Dried pellets were snap-frozen in liquid
nitrogen and stored at80C before protein extraction, and differ-
entiated myotubes (D4 and D8 in differentiating media) grown on
0.5% gelatine-coated glass coverslips were ﬁxed for 10 min in 4%
PFA before being processed for immunostainings.
PFA-ﬁxed cells were blocked in 5%BSAdiluted in PBS and immu-
nostained with the use of subsequent primary antibodies: MF20
(from DSHB, Iowa City, IA, USA), anti-a actinin (Sigma-Aldrich,
Saint-Quentin, France), and anti-titin (Novocastra, Newcastle,
UK) mouse monoclonal antibodies; anti-FHL1 (ARP34378_T100;
AVIVA Systems Biology, San Diego, CA, USA), anti-lamin A and C
(Santa Cruz, CA, USA), anti-emerin (generously provided by
Glenn Morris, NEWI, UK), and rabbit polyclonal antibodies, fol-
lowed by secondary Alexa568-conjugated anti-mouse IgG or
Alexa488-conjugated anti-rabbit IgG (Invitrogen, Cergy Pontoise,
France). Images were collected with a Carl Zeiss Axiophot1 micro-
scope. These different immunostainingswere used for fusion index
calculation. Fusion index is deﬁned as the number of nuclei
in myotubes to total nuclei ratio and was calculated after 4 and
8 days in DM in three independent experiments per individual
and per time points.
Protein Analysis
Proteins were extracted either from skeletal muscle fragments
(one healthy male control and ﬁve male patients: F8-6, F321-3,
F1292-1, F1328-4, and F1328-17) or from pelleted myoblasts
(patient F997-5).Muscle samples were homogenized with FastPrep
in total protein extraction buffer (50mMTris-HCl, pH 7.5, 2% SDS,
250 mM sucrose, 75 mM urea, 1 mM DTT) and with protease
inhibitor (25 mg/ml Aprotinin, 10 mg/ml Leupeptin, 1 mM 4-[2-
aminoethyl]-benzene sulfonylﬂuoride hydrochloride and 2mM
Na3VO4). Pelleted cells were extracted with the same buffer. Total
protein extracts (50 mg for analysis of FHL1 expression or 20 mg
for differentiation kinetic study) were separated on 15% and 10%
SDS-PAGE for FHL1 expression and differentiation studies, respec-
tively. Membranes were blocked in 5% skim milk in TBS-tween20
and hybridized with anti-FHL1 (ab58067, directed against the
N-terminal domain of FHL1A, FHL1B, and FHL1C), anti-myogenin
(ab1835) (both purchased fromAbCam,Cambridge, UK), anti-a ac-
tinin, or anti-vinculin (both from Sigma-Aldrich, Saint-Quentin,
France) mouse monoclonal antibodies and with secondary rabbit
anti-mouse IgGHRP-conjugated antibody (Dako, Trappes, France).
Immunoblots were visualized with Immobilon Western Chemilu-
minescent HRP Substrate (Millipore, Saint Quentin en Yvelines,
France) on a G-Box systemwithGeneSnap software (Ozyme,Mon-
tigny le Bretonneux, France).
Statistical Analysis
One-way analysis of variance was performed on fusion index data
with SigmaStat 3.5 software. Statistical signiﬁcancewas assumed at
p < 0.05.ber 11, 2009
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Figure 1. Pedigrees of the X-Linked EDMD Families
Males are depicted by squares, females by circles. Subjects presenting muscle involvement are indicated by right-half-ﬁlled symbols.
Subjects presenting cardiac disease are indicated by left-half-ﬁlled symbols. Questionmarks indicate uncertain phenotype status. Arrows
indicate the family index case. M: mutated; NM: nonmutated. Families F83, F997, and F1328 had whole-genome scan analysis. Family
F997 originates from Saudi Arabia and F321 from Japan, whereas others are of European descent.Results
Identiﬁcation of the EDMD Cohort
Among the 2200 patients referred to our institutions for
EMD and LMNA gene analysis, a subgroup of 588 index
cases corresponding to the inclusion criteria were identi-
ﬁed as harboring an EDMD phenotype. LMNA or EMD
genes were found to be mutated in 156 cases (26.5%)
and 50 cases (8.5%), respectively. The remaining 382
patients (65%; 280 males and 102 females) were consid-
ered as EDMD cases orphan of molecular diagnosis. For
these latter patients, a deﬁnite family history was found
in 90 patients (23.5%), whereas the remaining patients
were considered to be isolated cases (170; 44.5%) or to
have an uncertain family history (122; 32%).The AmericanWhole-Genome Scan Analysis
For six informative families comprising a total of 16 affected
and 33 nonaffected members, we performed whole-
genome scan analysis. Three of the families (F83, F997
and F1328) were compatible with anX-linked transmission
(Figure 1 and Figure S1). Linkage analysis of the consan-
guineous family F997with three affected brothers excluded
an autosomal-recessive transmission and detected a strong
linkage to locus Xq26.3. As for the F83 and F1328 families,
linkage analysis detected the same locus but with a smaller
size, spanning 16 megabases between SNP rs4281231 and
SNP rs4824862 (Figure 2). The cumulative LOD score on
the three familieswas 3.010 (Figure 2). For the three remain-
ing families, the linkage analysis pointed toward other
potential loci that are under analysis.Journal of Human Genetics 85, 338–353, September 11, 2009 341
Mutation Screening of FHL1
Among the 100 genes with an HGNC name located in the
locus identiﬁed on chromosome X, the FHL1 gene was
a good candidate because it was highly expressed in skel-
etal and cardiac muscles and has been implicated in other
muscle diseases.20–22 We therefore directly sequenced the
coding regions and ﬂanking splice sites of this gene. In
family F997, we identiﬁed a T>G transversion on the last
codon of the gene in exon 8 (c.841T>G [p.X281E], Table 1)
in the DNA of the three affected brothers (Figure 3). This
transversion suppresses the FHL1A termination codon,
predicting a larger protein with 52 additional amino
acids at the C-terminal end of the FHL1A isoform
(Figure 4). In family F1328, we detected a missense muta-
tion (c.827G>A [p.C276Y], Figure 3 and Table 1) in exon 8,
affecting a highly conserved cysteine of the LIM4 domain
present only in the FHL1A isoform. Ampliﬁcation of
exons 5 and 6 on the DNA of affected members of
family F83 was impossible. After long-range PCR from
exons 4 to 8, we detected a smaller PCR product in the
DNA of the two affected brothers that was also present
at a heterozygous state in the mother’s and sister’s DNA,
in comparison to control DNA. Sequencing of this shorter
PCR fragment revealed a genomic deletion of 1440 bp,
encompassing exons 5 and 6, deleting in frame 357 bp
of the coding sequence of FHL1A and FHL1B isoforms
Figure 2. LOD Score Profile of the Multipoint Linkage Per-
formed on the X Chromosome
Markers rs4281231 (position 124.82 Mb) and rs4824862 (position
140.10 Mb) encompass a 16 Mb region including 151 of the 1680
SNPs selected on the X chromosome and three microsatellites
(DXS8074 at position 133.91 Mb, intra FHL1 at position 135 Mb,
DXS8094 at position 136.064 Mb). The overall LOD score for the
three families (F83, F997, F1328) reaches a maximum of 3.010
near the FHL1 position. The analysis with cluster option led to
the same proﬁle and maximum LOD score.342 The American Journal of Human Genetics 85, 338–353, Septem(c.332_688del [p.G111_T229delinsG]), and deleting out
of frame 170 bp of the FHL1C coding sequence
(c.332_501del [p.D112FfsX51]; Figure 3 and Table 1).
These deletions lead to shorter FHL1A, FHL1B, and
FHL1C proteins lacking part of the LIM2 domain and
the entire LIM3 domain, together with part of the LIM4
domain for FHL1A. Mutated FHL1A and FHL1C are iden-
tical: in FHL1C, the deletion is thought to introduce
a frameshift within exon 5, but the junction with exon 8
reintroduces a frame that potentially leads to a pseudo
LIM4 domain, like that which occurs in FHL1A (Figures
3 and 4). FHL1B still contains its binding domain to
RBP-J, whereas FHL1C loses it. The identiﬁcation of FHL1
Table 1. Genomic and Protein Nomenclatures of FHL1 Mutations
According to the Affected Isoforms
FHL1 Isoform
(A, B, C) FHL1 Mutation Protein Nomenclature
Family F8
A c.625T>C p.Cys209Arg
B c.625T>C p.Cys209Arg
C - -
Family F11
A c.817dup p.Cys273LeufsX11
B c.973þ41dup (30UTR) -
C c.585þ41dup (30UTR) -
Family F83
A c.332_688del p.Gly111_Thr229delinsGly
B c.332_688del p.Gly111_Thr229delinsGly
C c.332_501del p.Asp112PhefsX51
Family F321
A c.469_470delAA p.Lys157ValfsX36
B c.469_470delAA p.Lys157ValfsX36
C c.469_470delAA p.Lys157ValfsX62
Family F997
A c.841T>G p.X281Glu
B c.973þ67T >G (30 UTR) -
C c.585þ67T>G (30 UTR) -
Family F1292
A c.371_372delAA p.Lys124ArgfsX6
B c.371_372delAA p.Lys124ArgfsX6
C c.371_372delAA p.Lys124ArgfsX6
Family F1328
A c.827G>A p.Cys276Tyr
B c.973þ53 (30 UTR) -
C c.585þ53 (30 UTR) -
Mutations indicated in italics affect the 30 untranslated region of the FHL1 gene.ber 11, 2009
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Figure 3. Distribution of the EDMD-
Related Mutations along the FHL1 Gene
and Corresponding RNA Isoforms
The FHL1 gene is composed of eight exons.
Exons 1 and 2 are noncoding, whereas
exons 3 to 8 are alternatively spliced and
give rise to three major transcribed iso-
forms: FHL1A, FHL1B, and FHL1C. Grey
squares represent alternatively spliced
exons. Translational start (ATG) and stop
(TAA or TGA) codons are indicated for
the three FHL1 isoforms. The seven FHL1
mutations identiﬁed in EDMD families
are depicted in blue (with corresponding
family number in bracket); they affected
exons 5, 6, and 8 and are missense or ins
and/or del truncating mutations. Muta-
tions related to X-SM21 (depicted in green),
X-MPMA20 (depicted in pink), RBM22
(depicted in brown), and RSS36 (depicted
in red) are all missense mutations and
essentially affect exons 4 or 5, except one
that affects exon 6.
Asterisk indicates the following informa-
tion: c.332_688del affects FLH1A and
FLH1B isoforms, and c.332_501del affects
the FHL1C isoform.mutations in these three families prompted us to directly
analyze this gene in additional EDMD patients for whom
X-linked inheritance seemed to be the most likely mode
of transmission (18 unrelated index cases) or in isolated
cases (49 males, nine females). We subsequently found
four additional mutations in three families (F8, F11, and
F321; Figure 1) and in one isolated male (F1292-1). Family
F8 displayed a missense mutation in exon 6 (c.625 T>C
[p.C209R], Figure 3 and Table 1), affecting an important
cysteine of the LIM3 domain of FHL1A and FHL1B iso-
forms (Figure 4). We identiﬁed in family F11 an insertion
of 1 bp in exon 8 (c.817dup [p.C273LfsX11]; Figure 3
and Table 1) introducing a frameshift affecting only the
FHL1A isoform that lacks the last two cysteines of the
LIM4 domain. Family F321 presented a deletion of 2 bp
in exon 5 (c.469_470delAA; Figure 3 and Table 1), predict-
ing a truncated protein with 35 out-of-frame new amino
acids in the C terminus of the FHL1A and FHL1B isoforms
(p.K157VfsX36) and 61 out-of-frame new amino acids
at the C terminus of FHL1C (p.K157VfsX62; Figure 4).
Finally, we found a deletion of 2 bp in exon 5
(c.371_372delAA [p.K124RfsX6]; Figure 3 and Table 1) in
the isolated patient F1292-1, predicting a truncated
protein with ﬁve out-of-frame new amino acids in the
LIM2 domain of the three FHL1 isoforms. All of these
mutations were absent from 200 control DNAs and
perfectly cosegregated with the disease (Figure 1).
Clinical Presentation of Patients with FHL1Mutations
Clinical evaluation of the seven index cases with muta-
tions, performed by the referring clinicians (A.V., B.E.,
C.T., M.A.S., M.H., S.Sa., S.Sp., T.S., T.V.), is summarized in
Table 2 and Table 3. More detailed clinical features found
in families with FHL1mutationswill be reported elsewhere.The AmericanOfnote, family F8’s index case has beenpreviously reported
as patient 4 byVoit et al.28 In all index cases, skeletalmuscle
symptoms preceded cardiac involvement. The age of onset
ranged from 4 to 48 years (14.7 5 15), with ﬁrst skeletal
muscle symptoms being joint contractures (four cases),
muscle weakness (one case) or both (two cases). The disease
course was progressive in all cases. All patients were still
ambulant after a disease duration ranging from6 to 30 years
(17.75 8.5). Among the seven index cases, the last neuro-
logical evaluation, performed at 18 to 54 years (32.4 5
12.1), revealed lower-limbmuscleweakness and/or wasting
of pelvic, peroneal, or pelvi-peroneal distribution in all
cases and upper-limb involvement in six of the cases,
usually in a scapular topography. Additional axial muscle
weakness and/or atrophy were observed in four patients,
and facial involvement was noticed in two patients.
Neck stiffness and rigid spine were observed in six and
ﬁve patients, respectively. Limb-joint contractures were
commonly observed: in ankles (seven patients), requiring
surgery in one of the patients; elbows (ﬁve patients); knees
(three patients); hips (two patients); wrists (one patient);
ﬁngers (one patient); and shoulders (one patient). Scoliosis
was present in three patients and required arthrodesis
in one. In addition, unusual symptoms were observed:
swallowing difﬁculties (one patient), dysphonia character-
ised by husky voice (three patients), muscle hypertrophy
(two patients), and ptosis (one patient). CK levels were
either normal or moderately elevated, up to 6-fold times
normal. Concerning the three patients showing dysphonic
voice, additional laryngeal investigation revealed abduc-
tion limitation of either the two vocal cords (two patients)
or one of the vocal cords (one patient), with normal electro-
myographic activities observed. These abnormalities sug-
gested vocal cord palsy.Journal of Human Genetics 85, 338–353, September 11, 2009 343
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Figure 4. Consequences of the Different EDMD Mutations on the Three FHL1 Isoforms
The three FHL1 protein isoforms are represented at the top of the picture, with indication of the position of the two EDMD missense
mutations. Below are presented the putative consequences at protein level of the missense mutation suppressing the FHL1A stop codon
and the four truncating mutations. Only FHL1 isoforms affected by the mutations are depicted.All index cases developed cardiac disease of variable
extent at an age ranging from 10 to 48 years (28.2 5 12)
(Table 3). Cardiac symptoms of onset were supraventric-
ular or ventricular arrhythmias (four patients), symptoms
of cardiac chamber hypertrophy (three patients), and
conduction defects (one patient). Last cardiac evaluation
(18 to 54 years, 32.5 5 12) revealed supraventricular or
ventricular arrhythmias in three patients, and conduction
defects were present in one patient. However, the most
striking ﬁnding was the presence of signiﬁcant cardiac
hypertrophy in four patients, biatrial dilation in one
patient, and both in one patient. Left ventricular function
was decreased in the two oldest patients and normal in the
ﬁve others. When respiratory evaluation was performed,
two patients showed severe impairment requiring nonin-
vasive ventilation. Finally, sudden death occurred in two
patients, at 31 and 51 years (one with severe hypertrophic
cardiomyopathy and the other with normal documented
LV function), and another died at 37 years from respiratory
insufﬁciency. None of the seven index cases had cardiac
transplantation.
Among the 68 available relatives, 38 (15 males, 23
females) were found to carry the FHL1mutations identiﬁed344 The American Journal of Human Genetics 85, 338–353, Septemin the seven index cases (Figure 1). Among these male rela-
tives, ten showed EDMD; four had isolated cardiac disease,
two presenting overt hypertrophic cardiomyopathy; and
one had unknown clinical status. Among them, one died
suddenly at 19 years (patient F1328-9) and two died in
other circumstances, at 23 and 27 years (patients F1328-8
and F8-27). Regarding female carriers, 16 were asymptom-
atic (age 26 to 81 years), and four had isolated cardiac
disease (age 36 and 74 years), two of them concomitantly
suffering from high blood pressure (patients F8-2 and F8-
22). The remaining three had either mild muscle involve-
ment, mainly spine rigidity (at 10 and 47 years [patients
F8-34 and F8-15]), or onset of motor difﬁculties with
hearth rhythm disturbances at 69 years (patient F8-4).
Histological Study
Prior to this study, muscle biopsies were performed for
diagnostic purpose in the seven index cases (Table 2).
They showed either unspeciﬁc myopathic features
(patients F11-5, F83-4, and F321-3) or a dystrophic pattern
(patients F8-6, F997-8, F1292-1, and F1328-4). Histological
reevaluation in three patients (F11-5, F997-8, and F1328-4)
showed ﬁber size variations and increase of interstitialber 11, 2009
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Family
Index Case
Onset (Age [Yrs] /
Symptoms)
Last Neurological Evaluation
Age
[yrs]
Weakness/Wasting Joint Contractures
Scoliosis Oth
Upper and
Lower Limbs
Axial/
Facial RS SN Elb. Ank. Others
F8-6b 11 / stiff neck,
unable to roll over
41 UL (scapulo-humeral),
LL (pelvic, distal)
Y Y Y Y small ﬁnger
joints, knees,
hips
Y
F11-5 6 / elbows and
Achilles tendons
contractures
30 UL (scapular),
LL (pelvic)
Axial Y Y Y Y knees mu
(rec
trap
bra
late
mu
due
pals
difﬁ
F83-4 14 / stiff neck 35 UL (scapular,
scapula alata),
LL (pelvic, peroneal),
Axial Y Y Y Y Y (scoliosis,
arthrodesisat
19 yo)
F321-3 4 / abnormal
gait, ankle joint
contracture
23 UL (scapular,
humeral),
LL (pelvic, peroneal)
Axial /
Facial
Y Y Y hips pto
F997-8 10 / stiff neck 18 UL (scapular),
LL (peroneal)
Y Y Y Y wrists,
knees
Y (scoliosis) dys
voc
F1292-1 10 / tiptoe walking 26 UL (humeral),
LL (peroneal)
Facial Y Y dys
voc
F1328-4 48 / difﬁculties in
climbing stairs and
get up from
squatting position
54 LL (pelvic) Axial Y Y shoulders mu
(pa
sho
Abbreviations are as follows: Ank, ankle; CK, creatine kinase; Elb, elbow; LL, lower limb; N, normal; RS, rigid spine; SN, stiff neck; UL, uppel limb; Y, yes; Yrs,
a x-fold normal level.
b Previously reported (patient 4, Voit et al.28).
Table 3. Cardiological and Respiratory Features of EDMD Family Index Cases
Family
Index
Case
Cardiac Disease Respiratory Involvement
Circumstance
of Death /
Age (Yrs)
Onset
(Age [Yrs] /
Symptoms)
Last Cardiac Assessment
FVC at
Last Evaluation /
Age (Yrs)
Mechanical
Ventilation /
Age (Yrs)Age
Conduction
Defects Arrhythmias
Chamber
Hypertrophy
Septum
Thickness
(mm)
LV
Dysfunction
F8-6 39 / AFl,
nocturnal
bradycardia,
SVES, VES,
42 N AFb, VES
and SVES
Y (LV, RV,
septal)
16a Y UK N Sudden
death / 51
F11-5 30 / Asthenia,
septal
hypertrophy
30 N N Y (septal) 23 N 40% / 30 NIV / 31 Sudden
death / 31
F83-4 27 / complete
RBBB, WPW
syndrome
35 N N N Normal N 25% / 31 NIV / 31 Respiratory
insufﬁciency / 37
F321-3 10 / Electric
heart
hypertrophy
23 N N Y (apex) 11.2 N UK N
F997-8 18 / Septal
hypertrophy
18 N N Y (septal) 20.7 N UK N
F1292-1 26 / AFb,
ischemic
stroke
26 RBBB AFb N (atrial
dilation)
Normal N 69.4% / 26 N
F1328-4 48 / AFl 54 N AFb Y (septal, LV)
with atrial
dilation
13 Y UK N
Abbreviations are as follows: AFb, atrial fibrillation; AFl, Atrial flutter; FVC, forced vital capacity; LV, left ventricle; N, no; NIV, noninvasive ventilation; RBBB, right
bundle branch block; RV, right ventricle; SVES, supraventricular extra systole; UK, unknown; VES: ventricular extra systole; WPW, Wolf-Parkinson-White; Y, yes.
a Postmortem analysis: severe left and right ventricular hypertrophic cardiomyopathy.tissue. Patient F11-5 showed myopathic changes associ-
ated with atrophic, angulated ﬁbers. Patient F1328-4
exhibited dissimilarities between two biopsies obtained
from different muscles: the quadriceps muscle appeared
dystrophic, with large variability in ﬁber size, internalisa-
tion of nuclei, rimmed vacuoles, and signiﬁcant increase
of interstitial tissue, whereas the deltoid muscle showed
only minimal unspeciﬁc changes, with mitochondrial
accumulation in subsarcolemmal position (Table 2 and
Figure 5). Menadione-NBT staining showed no reducing
bodies (RB) in the three reevaluated patients (Figure 5).
Results of immunostaining against myoﬁbrillar proteins
aB-crystallin, desmin, and myotilin were normal without
the presence of aggregates (data not shown). FHL1 immu-
noﬂuorescence studies were available for patients F1328-4
(not shown) and F997-8 (Figure 6A). On longitudinal and
transversal muscle sections, the immunoreactivity for
FHL1 was strongly reduced and the remaining FHL1
protein observed was mainly localized in and/or close to
the nucleus. Immunoﬂuorescence analysis of lamin A
and C and emerin on muscle sections of patients F1328-4
and F997-8 showed no difference in comparison to that
of a healthy control subject (Figure S2).
Protein Expression Study
When available, we used patient muscle biopsies or
cultured myoblasts to check the consequences of the346 The American Journal of Human Genetics 85, 338–353, Septemdifferent FHL1 mutations in terms of expression level and
presence of truncated proteins. Immunoblot analysis using
an antibody detecting an N-terminal epitope common to
the three major isoforms showed a strong expression of
FHL1A in control muscle biopsy (Figure 6B, upper panel),
whereas FHL1B and FHL1C were much less expressed
and detected only when membrane was overexposed for
5 min (Figure 6B, middle panel). Protein analysis of patient
biopsies or cultured myoblasts clearly showed a moderate
(patient F8-6; Figure 6B, upper panel) to strong (patients
F321-3, F997-5, F1292-1, F1328-4, and F1328-17) decrease
in FHL1 expression level (Figure 6B, middle panel). Trun-
cated or extended mutated FHL1 proteins were observed
at expected molecular weight (37.5 kDa and 14.5 kDa for
patients F997-5 and F1292-1, respectively). Surprisingly,
the band detected for patient F321-3 did not correspond
to the truncated FHL1A/B isoform (with expected molec-
ular weight being 13.5 kDa) but, rather, corresponded
to the truncated FHL1C (expected molecular weight of
24.5 kDa instead of 22 kDa for full-length FHL1C).
Differentiation and Immunoﬂuorescence Analysis
of Primary Myoblasts
To analyze the functional consequences of FHL1 muta-
tions, we induced primary myoblasts from patients
F321-3 and F997-5 to differentiate in culture by switching
conﬂuent myoblasts to DM and analyzed myogenin andber 11, 2009
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Figure 5. Muscle Histology of Patients
Haematoxylin and eosin (HE), Gomori trichrome (GT), andMenadione-nitroblue tetrazolium (Menadione-NBT) stainings on quadriceps
biopsies of patients F11-5, F997-8, and F1328-4 and an additional biopsy of deltoid muscle of patient F1328-4. With Menadione-NBT
stain, type II muscle ﬁbers appear as dark purple ﬁbers. Scale bar represents 100 mm.a-actinin expression at different time points (Figure 7A).
The expression of the differentiation factor myogenin,
absent in myoblasts, was induced after 24 hr in DM in
control cells (Figure 7A). In F321-3 cells, induction of
myogenin was low after 48 hr in DM and reached normal
expression levels only after 72 hr in DM. In F997-5 cells, we
were able to detect a very faint myogenin signal only
after 96 hr in DM. Myogenin is a transcription factor,
which switches on the myogenic program, resulting in
the expression of muscle-speciﬁc proteins as well as sarco-
meric proteins, such as a-actinin. In control myoblasts and
during the ﬁrst hours in DM, a-actinin expression was very
low, but increased by 48 hr in DM (i.e., 24 hr after myoge-
nin expression). In F321-3 cells, the increase in a-actinin
expression also appeared 24 hr after myogenin expression
had started. The increase in a-actinin expression was not
detected in F997-5 cells even after 96 hr in DM. However,
at that time, myogenin expression was only faintly ex-
pressed in F997-5 cells. Myoblasts fusion takes place after
myogenin induction. Considering the delay in myogenin
expression, we evaluated myoblast fusion by measuring
fusion index after 4 and 8 days in DM (Figure 7B). After
4 days in DM, control cells had 24% (5 3%) to 66%
(5 13%) of nuclei belonging to myotubes, whereasThe AmericanF321-3 cells had only 3% (5 3%) of nuclei in myotubes
and F997-5 cells have none. After 8 days in DM,
fusion index increased in all cultures. Control cells had
reached 59% (5 7%) to 73% (5 6%) of nuclei inmyotubes,
whereas F321-3 cells had reached 43% (5 8%) and fusion
of F997-5 cells was still severely delayed, at only 4%
(5 1%).
Finally, sarcomeric proteins have to assemble to form the
contractile apparatus. Some studies have implicated FHL1
in sarcomere assembly.19 Hence, we checked the putative
impact of FHL1 mutations on sarcomere formation in
control and patient myotubes after 8 days in DM. We
studied both thin and thick line formation by staining
for a-actinin and titin, respectively (Figure 7C). Despite
fewer myotubes in F321-3 and F997-5 cultures, we were
able to ﬁnd normally organized a-actinin and titin
proteins. Moreover, we used emerin and lamin A and C
immunostaining to look at their localization in FHL1-
mutated myotubes. No difference was observed in compar-
ison to control myotubes. Therefore, the two FHL1 muta-
tions identiﬁed in families F321 and F997 induced a delay
in myogenin activation and, hence, in myoblast fusion,
with a more severe impact for the mutation found in
family F997. None of the analyzed mutations seemed toJournal of Human Genetics 85, 338–353, September 11, 2009 347
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Figure 6. Immunostaining and Immunoblotting for FHL1 Showed a Strong Reduction in FHL1 Protein Expression
(A) Fluorescent immunostaining against FHL1 (green), with the use of the AVIVA antibody directed against the C-terminal domain of
FHL1A on longitudinal and transversal muscle sections from patient F997-5 and one healthy control.
(B) Immunoblotting of 50 mg total protein extract from patient biopsies (F8-6, F1328-4, F1328-17, F321-3, and F1292-1) and from
cultured primary myoblasts (F997-5), with the use of the FHL1 antibody from Abcam that detected the N-terminal domain common
to the three FHL1 isoforms. Themembrane was overexposed for 5min to allow for the detection of wild-type FHL1B and FHL1C isoforms
and most of the mutated proteins. Asterisks are used as follows: *, expected size of full-length FHL1A protein: 31.5 kDa; **, expected size
of F997 FHL1A protein: 37.5 kDa; ***, expected size of F321 FHL1C protein: 24.5 kDa; ****, expected size of F1292-1 FHL1A, FHL1B, and
FHL1C protein: 14.5 kDa. Vinculin was used as a loading control.have an impact on sarcomere formation or emerin and
lamin A/C localization in myotubes.
Discussion
Sincetheﬁrst reportofEDMD29and its recognitionasa sepa-
rate clinical and genetic entity,30 the implication of EMD
and LMNA genes5,6 has allowed precise molecular genetic
EDMD diagnosis but does not account for all EDMD
cases.10,11,31 For the identiﬁcation of other causative genes,
a large cohort of EMD- and LMNA-nonmutated EDMD
patients has been selected, and a whole-genome scan al-
lowedus to identify linkage to chromosomeXq26.3 in three
families.We report here, for the ﬁrst time to our knowledge,
seven FHL1 gene mutations associated with EDMD.
FHL1 Mutations Cause X-Linked EDMD
The seven index cases displayed the typical triple muscle-
joint-heart involvement of EDMD. Early joint contractures
occurred and involved the neck, spine, elbow, and
Achilles tendons, concomitantly with a progressive muscle
involvement of the four limbs, with a predominant
scapulo-humeral and pelvic and/or peroneal topography.
Secondarily, cardiac disease, mainly with arrhythmias and
cardiac hypertrophy, appeared and was highly life threat-
ening, being responsible for the sudden death of at least
two affected males, even despite normal cardiac function.
The EDMD patients reported here are different from
other FHL1-related disease patients20–22 and display several
speciﬁc features. First, histological studies in our patients
showed dystrophic or mostly nonspeciﬁc myopathic
patterns but no RB. Therefore, our patients are different348 The American Journal of Human Genetics 85, 338–353, Septemfrom RBM patients22 even if a recent report suggested
that a subgroup of RBMpatientsmay show EDMD features,
as indicated by an RBM patient with early joint contrac-
tures, rigid spine, and dilated cardiomyopathy (patient 8
in 32). In addition, none of our cases had congenital or
early childhood onset, as in RBM.22
Second, some of our cases displayed heart (5 of 7) and
muscle (2 of 7) hypertrophy, features also reported in
X-MPMA.20 Interestingly, predominant EDMD cardiac
features are conduction and/or rhythm defects,1 which
in patients with EMD and LMNAmutations evolve toward
dilated cardiomyopathy.1,33 Therefore, the presence of
cardiac hypertrophy in an EDMD patient should prompt
clinicians to screen for FHL1. As for muscle hypertrophy,
it has been observed in some rare LMNA-related cases
(G.B., unpublished data), but it is clear that X-MPMA is
a relevant differential diagnosis of FHL1-related EDMD
cases.
Third, three of our index cases had a striking vocal cord
palsy revealed by dysphonia without a neuropathic or
myopathic pattern at electromyographic examination.
Speech abnormalities or vocal cord palsy have been
reported in myopathies such as myotilinopathies34 and
distal myopathy with vocal cord and pharyngeal weak-
ness35 but never in EDMDor in other FHL1-related diseases.
Its association with the EDMDphenotype should therefore
also prompt FHL1 screening. Further investigations have
to be performed in order to elucidate the pathomechanism
of vocal cord involvement in these patients with FHL1
mutations.
Of signiﬁcant importance is that four males and one
female among the mutation-bearing relatives had isolatedber 11, 2009
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Figure 7. Differentiation Study Showed Major Differentiation Delay without Sarcomere-Formation Defects
(A) Immunoblot from control no. 3, patient F321-3, and patient F997-5 cultured myoblasts induced to differentiate for 0, 5, 10, 24, 48,
72, and 96 hr in differentiation medium (DM). Expression of myogenin was delayed in patients in comparison to healthy controls (only
control no. 3 is shown; similar results were obtained with controls no. 1 and no. 2). Expression of a-actinin in patient F321-3 was upre-
gulated 24 hr after myogenin expression had started, as in control cells, whereas for patient F997-5, no upregulation of a-actinin was
detected. Vinculin was used as loading control.
(B) Fusion index of F321-3 and F997-5 primary myoblasts compared to three healthy controls after 4 and 8 days in DM. p < 0.05.
Symbols are used as follows: * and @, patients versus cont1 at J4 and J8, respectively; # and &, patients versus cont2 at J4 and J8, respec-
tively; $ and £, patients versus cont3 at J4 and J8, respectively.
(C) Immunostainings of myotubes of two controls, F321-3 and F997-5, after 8 days in DM. The upper part shows representative pictures
of emerin (green) and a-actinin (red) stainings, whereas the lower part shows representative pictures of lamin A and C (green) and titin
(red) stainings. Nuclei are stained in blue by DAPI. Scale bar represents 20 mm.hypertrophic cardiomyopathy (families F11 and F1328),
suggesting that FHL1 mutation may lead to isolated
cardiac disease. We therefore propose that FHL1 screening
should be considered in patients displaying isolated
cardiac disease, notably hypertrophic cardiomyopathy,
even in the absence of any family history of skeletal muscle
involvement.
Finally, as previously reported for RBMandX-SM,21,22 we
observed a high frequency of symptomatic female carriers
in two of our families (F8 and F11), which may suggest
a primary dominantly inherited disease. As for other
X-linked diseases, this could be explained by a skewed X
chromosome inactivationor a dominant-negative function
ofmutated FHL1 proteins. On the other hand, the presence
of consanguinity (family F997) may suggest an autosomal-
recessive mode of inheritance and lead to some diagnosticThe Americandilemma. Nevertheless, the absence of male-to-male trans-
mission and/or the exclusive male involvement should
suggest an X-linked transmission.
Extension of the FHL1-Related Disease Spectrum
The identiﬁcation of FHL1 mutations in EDMD extends
the spectrum of FHL1-related diseases, after the description
of X-MPMA,20 X-SM,21 and RBM.22 Interestingly, recent
reports clariﬁed the FHL1-related disease nosology. Indeed,
muscle biopsies from patients of the original X-SM
family21 were found to contain menadione-NBT-positive
RB, suggesting that this family, in fact, represents a milder
form of RBM.32 Along the same line, a patient with a prom-
inent rigid spine (RSS) showed RB in his muscle biopsy.36
Consequently, FHL1-related disorders may be categorized
into two main subgroups. The ﬁrst is the ‘‘RB subgroup,’’Journal of Human Genetics 85, 338–353, September 11, 2009 349
which includes RBM, X-SM, and RSS, in which the hall-
mark is the typical histopathological ﬁnding of RB. Besides
this remarkable common histological marker, the RB sub-
group patients’ clinical spectrum seems to include severe
conditions with congenital or early childhood onset,
delayed motor milestones, and rapid loss of ambulation,
as well as a later-onset and less progressive condition that
may not lead to loss of ambulation.32 Only one patient
had an overt cardiac disease consistent with dilated cardio-
myopathy at 18 years of age.32 The second subgroup,
with the later-onset phenotype, may comprise EDMD
and X-MPMA patients.20 Interestingly, respiratory insufﬁ-
ciency seems to be a frequent feature in both subgroups
(present report and 20,32).
The EDMD-Related FHL1Mutations Exhibit a Speciﬁc
Pattern
Among the seven FHL1 gene mutations we report here,
two were missense mutations affecting highly conserved
cysteines of LIM3 and LIM4 domains, one abolished the
FHL1A stop codon, and four were truncating mutations
not reported in FHL1 before. Unlike mutations previously
described in other phenotypes, the EDMD mutations
were preferentially located in the most distal exons of
FHL1 (exons 5 to 8), whereas previously reported muta-
tions preferentially affected exons 4 and 5 of the gene
(Figure 3).20–22,36 In contrast to other FHL1-related diseases
in which only the LIM2 domain of the three FHL1 isoforms
was affected, the EDMD-related FHL1 mutations impaired
the three FHL1 isoforms to various degrees (Figure 4). They
altered either only the FHL1A isoform (F11, F997, F1328)
or the three isoforms that were differently modiﬁed, result-
ing in various new truncated proteins (F83, F321, F1292) or
carrying a missense mutation affecting FHL1A and FHL1B
(F8). To date, FHL1 gene mutations account for at least
1.2% of our EDMD cohort (7/588 EDMD index cases, but
the entire cohort has not yet been completely tested) and
do not explain all of our isolated males and likely X-linked
patients not carrying a mutation in EMD. We have identi-
ﬁed other loci that are still under analysis in other informa-
tive families (data not shown). Therefore, additional
genetic heterogeneity is expected for EDMD.
Regarding the possible genotype-phenotype relations,
the type of mutations and their location seem to be
crucial. Indeed, mutations associated with the RB sub-
group21,22,36,37were allmissenseor short in-framedeletions
(deletion of one or three amino acids) affecting highly
conserved cysteine and histidine of the LIM2 domain of
the three FHL1 isoforms.13 Histidine 123 and cysteine 153
appeared as hot-spot mutational sites in RBM patients
(Figure 3).22,32,37 To date, all reported mutations affecting
these conserved residues in the LIM2 domain of FHL1
have led to the formation of reducing bodies. In contrast,
mutations identiﬁed in the EDMD and X-MPMA20
subgroup were either missense or truncating mutations
affecting themost distal domains of FHL1 proteins (Figures
3 and 4). Mutations affecting the LIM2 domain in EDMD350 The American Journal of Human Genetics 85, 338–353, Septemand X-MPMA were either in-frame or out-of-frame dele-
tions: one short in-frame insertion in X-MPMA20 and small
or large out-of-frame deletions in EDMD (our data). This
difference may be at the origin of the absence of RB in
EDMD andX-MPMA patients. So far, no hot-spot mutation
was observed for this subgroup. The number of published
FHL1mutations is still limited, and additional reports will
help to conﬁrm these genotype-phenotype relations.
EDMD-Related FHL1 Mutations Lead to Reduction
of Protein Expression
As previously reported,14–18 we also detected strong expres-
sion of FHL1A and low expression of FHL1B and FHL1C
in skeletal muscle biopsies from control individuals
(Figure 6). In all tested patient biopsies or myoblasts,
FHL1A expression was severely reduced, except in one
case (F8, missense mutation), in which only moderate
reduction was observed. However, we always detected
the truncated or extended proteins in low amounts in all
tested cases, even in out-of-frame deletions (F321 and
F1292) or a stop codon mutation (F997). Thus, as for
EMD-related EDMD diagnosis,38 immunoblotting can be
used for diagnosis before the complete sequencing of the
gene.
So far, only FHL1A expression was analyzed in the other
FHL1-related diseases. It was found to be severely reduced
in X-MPMA,20 whereas it was either only slightly decreased
in X-SM21 and in late-onset RBM cases37 or increased in
early-onset RBM cases.22 Thus, one can see an inverse rela-
tion between duration of the symptoms at the time of the
biopsy and expression level of FHL1A, as previously stated
for X-SM.21 In other words, a reduced level of FHL1 expres-
sion seems to be less deleterious for skeletal muscle than
persistence and accumulation of a mutated FHL1 protein.
Missense or small in-frame mutations in the LIM2 domain
are identiﬁed in disorders with RB (RBM, RSS, X-SM) that
only show slight decrease or accumulation of FHL1A,
whereas missense or truncating mutations in the distal
domains of FHL1, identiﬁed in EDMD and X-MPMA, lead
to severe reduction of the protein level. In addition, trun-
cated proteins are expressed in EDMD cases. Thus, again,
the localization and/or the type of the FHL1 mutation
seems to be important.
Pathophysiological Mechanisms of EDMD-Related
FHL1 Mutations
Two recent papers have pointed out the role of FHL1 in the
regulation of the ultra-rapid activating delayed rectiﬁer Kþ
current and atrial arrhythmia,39,40 which may explain the
typical arrhythmia and/or conduction defect observed in
several EDMD patients with FHL1 mutations. However,
cardiac hypertrophy observed in several EDMD patients
was more difﬁcult to understand, considering that FHL1
knockout mice show blunted response to stress-induced
cardiac hypertrophy,41 whereas EDMD patients with
FHL1mutations showed reduced FHL1 expression. Several
hypotheses may explain this discrepancy. First, we hadber 11, 2009
access only to skeletal muscle biopsies, and thus FHL1
expression might be different in cardiac muscle. Second,
EDMD-related FHL1 mutations differently affect the three
isoforms. The residual expression in the heart of the modi-
ﬁed FHL1 isoforms might be sufﬁcient to lead to cardiac
arrhythmias and hypertrophy. Third, as we have shown
in skeletal muscles, the truncated FHL1 proteins are
expressed at low level and may have a dominant-negative
effect on still uncharacterized proteins, as has been shown
for RBM mutations on the NFAT protein.42 Finally, before
interaction between FHL1 and titin has been identiﬁed,41
a recent report has shown a relationship between the
level of titin (N2B region)-FHL2 interaction and the devel-
opment of dilated (DCM) or hypertrophic (HCM) cardio-
myopathy, a decrease of the interaction being related to
DCM and an increase in the interaction being related to
HCM.43
Concerning the skeletal muscles, our in vitro experi-
ments have shown that the reduced FHL1 expression has
an impact on myogenin expression and myoblast fusion.
These results were obtained only on two different patient
primary cells and therefore may be still considered as
preliminary. Delay in myogenin expression and myoblast
fusion was reported in other muscular disorders.44,45
However, these observations in FHL1-mutated cells are in
accordance with the recent study from Cowling et al.,42
which showed a correlation between FHL1 expression
level and myotube size.42 Further studies are needed to
clarify the speciﬁcity of these observations. Finally, a role
in sarcomere organization has been attributed to FHL1.19
However, in our in vitro myoblast differentiation assay,
performed on FHL1-mutated myoblasts, sarcomere forma-
tion appeared to be undisturbed.
It is important to note that the different FHL1 isoforms
have been described as localizing to separate subcellular
compartments of the muscle cell: sarcomere I-band and
Z-line, as well as costameres for FHL1A,19 the nucleus for
FHL1C14 and FHL1B, which is shuttling between the
nucleus and the cytoplasm.16,17 The FHL1 isoforms have
speciﬁc functions at these different locations. FHL1A has
been described as playing an important role in the mecha-
nism of pathological hypertrophy by sensing biomechan-
ical stress responses via activation of the ERK pathway,41
whereas FHL1C (and probably FHL1B) isoforms that
localize to the nucleus are thought to inhibit Notch
signaling by the speciﬁc interaction with the RBP-J tran-
scription factor.14 In a context-dependent manner, Notch
signals can promote or suppress cell proliferation, cell
death, acquisition of speciﬁc cell fates, or activation of
differentiation programs. This occurs in cells throughout
development of the organism and during themaintenance
of self-renewing adult tissues, including skeletal muscles
(reviewed in 46). Hence, FHL1 proteins have dual functions
in the cell: the maintenance of structural integrity and
the regulation of cell signaling. Interestingly, theses
functions are shared by emerin and lamin A and C
proteins.8,9,47–49 Moreover, in this study, we have shownThe Americanthat EDMD-related patient myoblasts with an FHL1muta-
tion have impaired differentiation, whereas several studies
have pointed out the role of emerin and lamin A and C in
skeletal muscle differentiation.50,51 Therefore, beside the
similarities in terms of EDMD phenotype, the mutations
that we found in FHL1 and mutations reported in LMNA
and EMD may be associated with similar pathophysiolog-
ical mechanisms.
Supplemental Data
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